Apparatus and method for wound volume measurement

Information

  • Patent Grant
  • 12029549
  • Patent Number
    12,029,549
  • Date Filed
    Tuesday, July 20, 2021
    3 years ago
  • Date Issued
    Tuesday, July 9, 2024
    4 months ago
Abstract
A method and apparatus for measuring a volume of a wound are described, the method comprising the steps of: applying a dressing over a wound, the volume of which is to be measured, the dressing including at least a sealing drape over the wound so as to create a sealed wound cavity; creating a vacuum in said wound cavity by vacuum pump means so as to produce a predetermined vacuum in the wound cavity; measuring a volume of air extracted from said wound cavity in producing said predetermined vacuum; and, calculating a volume of said wound.
Description

The present invention relates to apparatus and a method for the measurement of wound volume to assess progress of wound healing particularly, though not exclusively, during topical negative pressure (TNP) therapy.


There is much prior art available relating to the provision of apparatus and methods of use thereof for the application of TNP therapy to wounds together with other therapeutic processes intended to enhance the effects of the TNP therapy. Examples of such prior art include those listed and briefly described below.


TNP therapy assists in the closure and healing of wounds by reducing tissue oedema; encouraging blood flow and granulation of tissue; removing excess exudates and may reduce bacterial load and thus, infection to the wound. Furthermore, TNP therapy permits less outside disturbance of the wound and promotes more rapid healing.


In our co-pending International patent application, WO 2004/037334, apparatus, a wound dressing and a method for aspirating, irrigating and cleansing wounds are described. In very general terms, this invention describes the treatment of a wound by the application of topical negative pressure (TNP) therapy for aspirating the wound together with the further provision of additional fluid for irrigating and/or cleansing the wound, which fluid, comprising both wound exudates and irrigation fluid, is then drawn off by the aspiration means and circulated through means for separating the beneficial materials therein from deleterious materials. The materials which are beneficial to wound healing are recirculated through the wound dressing and those materials deleterious to wound healing are discarded to a waste collection bag or vessel.


In our co-pending International patent application, WO 2005/04670, apparatus, a wound dressing and a method for cleansing a wound using aspiration, irrigation and cleansing wounds are described. Again, in very general terms, the invention described in this document utilises similar apparatus to that in WO 2004/037334 with regard to the aspiration, irrigation and cleansing of the wound, however, it further includes the important additional step of providing heating means to control the temperature of that beneficial material being returned to the wound site/dressing so that it is at an optimum temperature, for example, to have the most efficacious therapeutic effect on the wound.


In our co-pending International patent application, WO 2005/105180, apparatus and a method for the aspiration, irrigation and/or cleansing of wounds are described. Again, in very general terms, this document describes similar apparatus to the two previously mentioned documents hereinabove but with the additional step of providing means for the supply and application of physiologically active agents to the wound site/dressing to promote wound healing.


The content of the above references is included herein by reference.


However, the above apparatus and methods are generally only applicable to a patient when hospitalised as the apparatus is complex, needing people having specialist knowledge in how to operate and maintain the apparatus, and also relatively heavy and bulky, not being adapted for easy mobility outside of a hospital environment by a patient, for example.


Some patients having relatively less severe wounds which do not require continuous hospitalisation, for example, but whom nevertheless would benefit from the prolonged application of TNP therapy, could be treated at home or at work subject to the availability of an easily portable and maintainable TNP therapy apparatus.


One particular area of wound therapy which is desirable is to monitor the volume of a wound during its treatment such as, for example, at dressing change time so as to be able to quantify the healing process. However, there are presently no simple and/or accurate tools with which to make this assessment of wound volume.


Methods which have been used have include measuring the length, width and depth of a wound and making some assessment from the dimensions but this is very inaccurate; Taking a tracing around the wound, calculating the area and taking depth measurements; filling the wound with a filler and measuring the wound volume based on a known density of the filler; and photographic methods. All of these prior methods involve making calculated guesses resulting in inaccurate volume figures or are time consuming or are rather impractical.


Desirably, wound volume should be measured when a dressing is changed at, for example, every few days so as to keep a continuous record of progress.


Whatever method was used it would result in the figures having to be stored in a file, for example, and generally not with the patient being treated.


It is an aim of the present invention to at least partly mitigate the above-mentioned problems.


According to a first aspect of the present invention there is provided a method of measuring a volume of a wound, the method comprising the steps of: applying a dressing over a wound, the volume of which is to be measured, the dressing including at least a sealing drape over the wound so as to create a sealed wound cavity; creating a vacuum in said wound cavity by vacuum pump means so as to produce a predetermined vacuum in the wound cavity; measuring a volume of air extracted from said wound cavity in producing said predetermined vacuum; and, calculating a volume of said wound.


According to a second aspect of the present invention there is provided apparatus for measuring the volume of a wound, the apparatus comprising: a dressing covering and sealing the wound to form a cavity over the wound; an aspiration conduit leading from the wound cavity to a waste canister; a vacuum source; and, flow measuring sensor means.


In one embodiment of the present invention, the volume of air may be measured by signals received from flow sensor means in an apparatus control system.


Desirably, the wound volume measurement may be made at a time of dressing change and with an empty waste canister.


Desirably, the wound may be dressed in the same manner as closely as possible each time so as to minimise variables due to differences in the type and degree of packing of the wound, for example. For example, the wound may be packed with suitable filler material (if large enough and if appropriate) such as gauze, foam or any other type of filler appropriate to the wound and the sealing drape may be applied such that when the filler is compressed by the applied vacuum to the predetermined vacuum pressure then the sealing drape may be flush, for example, with the patient's sound flesh surrounding the wound. This is explanation is merely exemplary but is intended to emphasize the desirability of a consistent manner of wound dressing.


The method of the present may be applied by apparatus for the provision of TNP therapy to a patient in almost any environment. The apparatus is lightweight, may be mains or battery powered by a rechargeable battery pack contained within a device (henceforth, the term “device” is used to connote a unit which may contain all of the control, power supply, power supply recharging, electronic indicator means and means for initiating and sustaining aspiration functions to a wound and any further necessary functions of a similar nature). When outside the home, for example, the apparatus may provide for an extended period of operation on battery power and in the home, for example, the device may be connected to the mains by a charger unit whilst still being used and operated by the patient.


The overall apparatus of which the present invention is a part comprises: a dressing covering the wound and sealing at least an open end of an aspiration conduit to a cavity formed over the wound by the dressing; an aspiration tube comprising at least one lumen therethrough leading from the wound dressing to a waste material canister for collecting and holding wound exudates/waste material prior to disposal; and, a power, control and aspiration initiating and sustaining device associated with the waste canister.


The dressing covering the wound may be any type of dressing normally employed with TNP therapy and, in very general terms, may comprise, for example, a semi-permeable, flexible, self-adhesive drape material, as is known in the dressings art, to cover the wound and seal with surrounding sound tissue to create a sealed cavity or void over the wound. There may aptly be a porous barrier and support member in the cavity between the wound bed and the covering material to enable an even vacuum distribution to be achieved over the area of the wound. The porous barrier and support member being, for example, a gauze, a foam, an inflatable bag or known wound contact type material resistant to crushing under the levels of vacuum created and which permits transfer of wound exudates across the wound area to the aspiration conduit sealed to the flexible cover drape over the wound.


The aspiration conduit may be a plain flexible tube, for example, having a single lumen therethrough and made from a plastics material compatible with raw tissue, for example. However, the aspiration conduit may have a plurality of lumens therethrough to achieve specific objectives relating to the invention. A portion of the tube sited within the sealed cavity over the wound may have a structure to enable continued aspiration and evacuation of wound exudates without becoming constricted or blocked even at the higher levels of the negative pressure range envisaged.


It is envisaged that the negative pressure range for the apparatus embodying the present invention may be between about −50 mmHg and −200 mmHg (note that these pressures are relative to normal ambient atmospheric pressure thus, −200 mmHg would be about 560 mmHg in practical terms). Aptly, the pressure range may be between about −75 mmHg and −150 mmHg. Alternatively a pressure range of up to −75 mmHg, up to −80 mmHg or over −80 mmHg can be used. Also aptly a pressure range of below −75 mmHg could be used. Alternatively a pressure range of over −100 mmHg could be used or over −150 mmHg.


The aspiration conduit at its distal end remote from the dressing may be attached to the waste canister at an inlet port or connector. The device containing the means for initiating and sustaining aspiration of the wound/dressing may be situated between the dressing and waste canister, however, in a preferred embodiment of the apparatus embodying the present invention, the device may aspirate the wound/dressing via the canister thus, the waste canister may preferably be sited between the wound/dressing and device.


The aspiration conduit at the waste material canister end may preferably be bonded to the waste canister to prevent inadvertent detachment when being caught on an obstruction, for example.


The canister may be a plastics material moulding or a composite unit comprising a plurality of separate mouldings. The canister may aptly be translucent or transparent in order to visually determine the extent of filling with exudates. However, the canister and device may in some embodiments provide automatic warning of imminent canister full condition and may also provide means for cessation of aspiration when the canister reaches the full condition.


The canister may be provided with filters to prevent the exhaust of liquids and odours therefrom and also to prevent the expulsion of bacteria into the atmosphere. Such filters may comprise a plurality of filters in series. Examples of suitable filters may comprise hydrophobic filters of 0.2 μm pore size, for example, in respect of sealing the canister against bacteria expulsion and 1 μm against liquid expulsion.


Aptly, the filters may be sited at an upper portion of the waste canister in normal use, that is when the apparatus is being used or carried by a patient the filters are in an upper position and separated from the exudate liquid in the waste canister by gravity. Furthermore, such an orientation keeps the waste canister outlet or exhaust exit port remote from the exudate surface.


Aptly the waste canister may be filled with an absorbent gel such as ISOLYSEL (trade mark), for example, as an added safeguard against leakage of the canister when full and being changed and disposed of. Added advantages of a gel matrix within the exudate storing volume of the waste canister are that it prevents excessive movement, such as slopping, of the liquid, minimises bacterial growth and minimises odours.


The waste canister may also be provided with suitable means to prevent leakage thereof both when detached from the device unit and also when the aspiration conduit is detached from the wound site/dressing.


The canister may have suitable means to prevent emptying by a user (without tools or damage to the canister) such that a full or otherwise end-of-life canister may only be disposed of with waste fluid still contained.


The device and waste canister may have mutually complementary means for connecting a device unit to a waste canister whereby the aspiration means in the device unit automatically connects to an evacuation port on the waste canister such that there is a continuous aspiration path from the wound site/dressing to an exhaust port on the device.


Aptly, the exhaust port from the fluid path through the apparatus is provided with filter means to prevent offensive odours from being ejected into the atmosphere.


In general terms the device unit comprises an aspirant pump; means for monitoring pressure applied by the aspirant pump; a flowmeter to monitor fluid flow through the aspirant pump; a control system which controls the aspirant pump in response to signals from sensors such as the pressure monitoring means and the flowmeter, for example, and which control system also controls a power management system with regard to an on-board battery pack and the charging thereof and lastly a user interface system whereby various functions of the device such as pressure level set point, for example, may be adjusted (including stopping and starting of the apparatus) by a user. The device unit may contain all of the above features within a single unified casing.


When the dressing is applied to the wound a volume of air is trapped under the sealing drape in the wound cavity. When the vacuum source such as a vacuum pump, for example, is started the wound cavity is evacuated to a predetermined vacuum such as by 0.1 of an atmosphere (i.e. about 76 mmHg below atmospheric pressure). In this case 0.1 of the volume of air in the wound cavity is removed and which is measured by the flow sensor means such as a flowmeter, for example, in the control and monitoring system. The volume of air removed will be proportional to the actual volume of the wound. The volumes of other parts of the apparatus such as the aspiration conduit, the waste canister, the vacuum pump and the flow conduits in the apparatus leading to the flow sensor may be measured and/or are known and constant factors for which a correction factor may be incorporated in memory means in the control system software.


Once the desired vacuum level is achieved and is steady at that level, the various factors may be computed by the software in the control system to calculate the wound volume. It is important that the desired vacuum is at a steady state and the vacuum source such as a vacuum pump may be running slowly or intermittently to achieve such a steady state due, for example, to a leak into the wound cavity through or around the sealing drape. The software may contain appropriate data relating to the vacuum pump operating regime to calculate the steady state leak rate and to enable the control and monitoring system to apply a suitable correction factor to allow for a steady state leak rate. Thus, when the wound cavity has achieved a steady state when the vacuum level pressure is at the desired value, what the flow sensor is reading is the actual leak rate which may be used by the software to compute the correction factor applicable.


Different wound filling materials may have different compressibility from each other. Gauze, for example, is made from material fibres which themselves are virtually incompressible at the levels of vacuum under consideration in the present invention; foam materials, however, are much more compressible and thus, correction factors need to be made to allow for the type of wound filling material in use. This may be easily achieved by test cavities of known volumes used to calibrate the apparatus for different filling materials and calculate appropriate correction factors.


As noted above it is desirable that at a time of dressing change the waste canister is empty since its empty volume forms part of the correction factor incorporated into the software. However, it is not necessary that the waste canister be empty so long as its free space is known so that a suitable factor may be entered into the control and monitoring system such as by a key pad associated with the apparatus device, for example.


In the present invention the device may have means such as LED display means, for example, of displaying and storing the volume of the wound as measured at each stage such as at each dressing change time, for example, so that a record exists of the progress of wound healing. Alternatively, the device may have an output to a separate display and/or recording device where data may be held and/or displayed.


In view of the fact that the device unit contains the majority of the intrinsic equipment cost therein ideally it will also be able to survive impact, tolerate cleaning in order to be reusable by other patients.


In terms of pressure capability the aspiration means may be able to apply a maximum pressure drop of at least −200 mmHg to a wound site/dressing. The apparatus is capable of maintaining a predetermined negative pressure even under conditions where there is a small leak of air into the system and a high exudate flow.


The pressure control system may prevent the minimum pressure achieved from exceeding for example −200 mmHg so as not to cause undue patient discomfort. The pressure required may be set by the user at a number of discreet levels such as −50, −75, −100, −125, −150, −175 mmHg, for example, depending upon the needs of the wound in question and the advice of a clinician. Thus suitable pressure ranges in use may be from −25 to −80 mmHg, or −50 to −76 mmHg, or −50 to −75 mmHg as examples. The control system may also advantageously be able to maintain the set pressure within a tolerance band of +/−10 mmHg of the set point for 95% of the time the apparatus is operating given that leakage and exudation rates are within expected or normal levels.


Aptly, the control system may trigger alarm means such as a flashing light, buzzer or any other suitable alarm means when various abnormal conditions apply such as, for example: pressure outside set value by a large amount due to a gross leak of air into system; duty on the aspiration pump too high due to a relatively smaller leakage of air into the system; pressure differential between wound site and pump is too high due, for example, to a blockage or waste canister full.


The apparatus of the present invention may be provided with a carry case and suitable support means such as a shoulder strap or harness, for example. The carry case may be adapted to conform to the shape of the apparatus comprised in the joined together device and waste canister. In particular, the carry case may be provided with a bottom opening flap to permit the waste canister to be changed without complete removal of the apparatus form the carry case.


The carry case may be provided with an aperture covered by a displaceable flap to enable user access to a keypad for varying the therapy applied by the apparatus.





In order that the present invention may be more fully understood, examples will now be described by way of illustration only with reference to the accompanying drawings, of which:



FIG. 1 shows a generalised schematic block diagram showing a general view of an apparatus and the constituent apparatus features thereof;



FIG. 2 shows a similar generalised schematic block diagram to FIG. 1 and showing fluid paths therein;



FIG. 3 shows a generalised schematic block diagram similar to FIG. 1 but of a device unit only and showing power paths for the various power consuming/producing features of the apparatus;



FIG. 4 shows a similar generalised schematic block diagram to FIG. 3 of the device unit and showing control system data paths for controlling the various functions and components of the apparatus;



FIG. 5 shows a perspective view of an apparatus;



FIG. 6 shows a perspective view of an assembled device unit of the apparatus of FIG. 5;



FIG. 7 shows an exploded view of the device unit of FIG. 6;



FIG. 8 shows a partially sectioned side elevation view through the interface between a waste canister and device unit of the apparatus;



FIG. 9 shows a cross section through a waste canister of the apparatus of FIGS. 5 to 8;



FIG. 10 shows a schematic cross section of a wound, the volume of which is to be measured, the wound having apparatus for the application of TNP therapy thereto;



FIG. 11 shows a graph of flow vs time of an example of wound volume measurement; and



FIG. 12 which shows a graph of flow against pressure in the wound cavity.





Referring now to FIGS. 1 to 4 of the drawings and where the same or similar features are denoted by common reference numerals.



FIG. 1 shows a generalised schematic view of an apparatus 10 of a portable topical negative pressure (TNP) system. It will be understood that embodiments of the present invention are generally applicable to use in such a TNP system. Briefly, negative pressure wound therapy assists in the closure and healing of many forms of “hard to heal” wounds by reducing tissue oedema; encouraging blood flow and granular tissue formation; removing excess exudate and may reduce bacterial load (and, therefore, infection). In addition the therapy allows for less disturbance of a wound leading to more rapid healing. The TNP system is detailed further hereinafter but in summary includes a portable body including a canister and a device with the device capable of providing an extended period of continuous therapy within at least a one year life span. The system is connected to a patient via a length of tubing with an end of the tubing operably secured to a wound dressing on the patient.


More particularly, as shown in FIG. 1, the apparatus comprises an aspiration conduit 12 operably and an outer surface thereof at one end sealingly attached to a dressing 14. The dressing 14 will not be further described here other than to say that it is formed in a known manner from well know materials to those skilled in the dressings art to create a sealed cavity over and around a wound to be treated by TNP therapy with the apparatus of the present invention. The aspiration conduit has an in-line connector 16 comprising connector portions 18, 20 intermediate its length between the dressing 14 and a waste canister 22. The aspiration conduit between the connector portion 20 and the canister 22 is denoted by a different reference numeral 24 although the fluid path through conduit portions 12 and 24 to the waste canister is continuous. The connector portions 18, 20 join conduit portions 12, 24 in a leak-free but disconnectable manner. The waste canister 22 is provided with filters 26 which prevent the escape via an exit port 28 of liquid and bacteria from the waste canister. The filters may comprise a 1 μm hydrophobic liquid filter and a 0.2 μm bacteria filter such that all liquid and bacteria is confined to an interior waste collecting volume of the waste canister 22. The exit port 28 of the waste canister 22 mates with an entry/suction port 30 of a device unit 32 by means of mutually sealing connector portions 34, 36 which engage and seal together automatically when the waste canister 22 is attached to the device unit 32, the waste canister 22 and device unit 32 being held together by catch assemblies 38, 40. The device unit 32 comprises an aspirant pump 44, an aspirant pressure monitor 46 and an aspirant flowmeter 48 operably connected together. The aspiration path takes the aspirated fluid which in the case of fluid on the exit side of exit port 28 is gaseous through a silencer system 50 and a final filter 52 having an activated charcoal matrix which ensures that no odours escape with the gas exhausted from the device 32 via an exhaust port 54. The filter 52 material also serves as noise reducing material to enhance the effect of the silencer system 50. The device 32 also contains a battery pack 56 to power the apparatus which battery pack also powers the control system 60 which controls a user interface system 62 controlled via a keypad (not shown) and the aspiration pump 44 via signals from sensors 46, 48. A power management system 66 is also provided which controls power from the battery pack 56, the recharging thereof and the power requirements of the aspirant pump 44 and other electrically operated components. An electrical connector 68 is provided to receive a power input jack 70 from a SELV power supply 72 connected to a mains supply 74 when the user of the apparatus or the apparatus itself is adjacent a convenient mains power socket.



FIG. 2 shows a similar schematic representation to FIG. 1 but shows the fluid paths in more detail. The wound exudate is aspirated from the wound site/dressing 14 via the conduit 12, the two connector portions 18, 20 and the conduit 24 into the waste canister 22. The waste canister 22 comprises a relatively large volume 80 in the region of 500 ml into which exudate from the wound is drawn by the aspiration system at an entry port 82. The fluid 84 drawn into the canister volume 80 is a mixture of both air drawn into the dressing 14 via the semi-permeable adhesive sealing drape (not shown) and liquid 86 in the form of wound exudates. The volume 80 within the canister is also at a lowered pressure and the gaseous element 88 of the aspirated fluids is exhausted from the canister volume 80 via the filters 26 and the waste canister exhaust exit port 28 as bacteria-free gas. From the exit port 28 of the waste canister to the final exhaust port 54 the fluid is gaseous only.



FIG. 3 shows a schematic diagram showing only the device portion of the apparatus and the power paths in the device of the apparatus embodying the present invention. Power is provided mainly by the battery pack 56 when the user is outside their home or workplace, for example, however, power may also be provided by an external mains 74 supplied charging unit 72 which when connected to the device 32 by the socket 68 is capable of both operating the device and recharging the battery pack 56 simultaneously. The power management system 66 is included so as to be able to control power of the TNP system. The TNP system is a rechargeable, battery powered system but is capable of being run directly from mains electricity as will be described hereinafter more fully with respect to the further figures. If disconnected from the mains the battery has enough stored charge for approximately 8 hours of use in normal conditions. It will be appreciated that batteries having other associated life times between recharge can be utilised. For example batteries providing less than 8 hours or greater than 8 hours can be used. When connected to the mains the device will run off the mains power and will simultaneously recharge the battery if depleted from portable use. The exact rate of battery recharge will depend on the load on the TNP system. For example, if the wound is very large or there is a significant leak, battery recharge will take longer than if the wound is small and well sealed.



FIG. 4 shows the device 32 part of the apparatus embodying the present invention and the data paths employed in the control system for control of the aspirant pump and other features of the apparatus. A key purpose of the TNP system is to apply negative pressure wound therapy. This is accomplished via the pressure control system which includes the pump and a pump control system. The pump applies negative pressure; the pressure control system gives feedback on the pressure at the pump head to the control system; the pump control varies the pump speed based on the difference between the target pressure and the actual pressure at the pump head. In order to improve accuracy of pump speed and hence provide smoother and more accurate application of the negative pressure at a wound site, the pump is controlled by an auxiliary control system. The pump is from time to time allowed to “free-wheel” during its duty cycle by turning off the voltage applied to it. The spinning motor causes a “back electro-motive force” or BEMF to be generated. This BEMF can be monitored and can be used to provide an accurate measure of pump speed. The speed can thus be adjusted more accurately than can prior art pump systems.


According to embodiments of the present invention, actual pressure at a wound site is not measured but the difference between a measured pressure (at the pump) and the wound pressure is minimised by the use of large filters and large bore tubes wherever practical. If the pressure control measures that the pressure at the pump head is greater than a target pressure (closer to atmospheric pressure) for a period of time, the device sends an alarm and displays a message alerting the user to a potential problem such as a leak.


In addition to pressure control a separate flow control system can be provided. A flow meter may be positioned after the pump and is used to detect when a canister is full or the tube has become blocked. If the flow falls below a certain threshold, the device sounds an alarm and displays a message alerting a user to the potential blockage or full canister.


Referring now to FIGS. 5 to 9 which show various views and cross sections of a preferred embodiment of apparatus 200 embodying the present invention. The preferred embodiment is of generally oval shape in plan and comprises a device unit 202 and a waste canister 204 connected together by catch arrangements 206. The device unit 202 has a liquid crystal display (LCD) 208, which gives text based feedback on the wound therapy being applied, and a membrane keypad 210, the LCD being visible through the membrane of the keypad to enable a user to adjust or set the therapy to be applied to the wound (not shown). The device has a lower, generally transverse face 212 in the centre of which is a spigot 214 which forms the suction/entry port 216 to which the aspiration means (to be described below) are connected within the device unit. The lower edge of the device unit is provided with a rebated peripheral male mating face 218 which engages with a co-operating peripheral female formation 220 on an upper edge of the waste canister 204 (see FIGS. 8 and 9). On each side of the device 202, clips 222 hinged to the canister 204 have an engaging finger (not shown) which co-operates with formations in recesses 226 in the body of the device unit. From FIG. 7 it may be seen that the casing 230 of the device unit is of largely “clamshell” construction comprising front and back mouldings 232, 234, respectively and left-hand and right-hand side inserts 236, 238. Inside the casing 230 is a central chassis 240 which is fastened to an internal moulded structural member 242 and which chassis acts as a mounting for the electrical circuitry and components and also retains the battery pack 246 and aspiration pump unit 248. Various tubing items 250, 252, 254 connect the pump unit 248 and suction/entry port 216 to a final gaseous exhaust via a filter 290. FIG. 8 shows a partially sectioned side elevation of the apparatus 200, the partial section being around the junction between the device unit 202 and the waste canister 204, a cross section of which is shown at FIG. 9. Theses views show the rebated edge 218 of the male formation on the device unit co-operating with the female portion 220 defined by an upstanding flange 260 around the top face 262 of the waste canister 204. When the waste canister is joined to the device unit, the spigot 214 which has an “O” ring seal 264 therearound sealingly engages with a cylindrical tube portion 266 formed around an exhaust/exit port 268 in the waste canister. The spigot 214 of the device is not rigidly fixed to the device casing but is allowed to “float” or move in its location features in the casing to permit the spigot 214 and seal 264 to move to form the best seal with the bore of the cylindrical tube portion 266 on connection of the waste canister to the device unit. The waste canister 204 in FIG. 9 is shown in an upright orientation much as it would be when worn by a user. Thus, any exudate 270 would be in the bottom of the internal volume of waste receptacle portion 272. An aspiration conduit 274 is permanently affixed to an entry port spigot 278 defining an entry port 280 to receive fluid aspirated from a wound (not shown) via the conduit 274. Filter members 282 comprising a 0.2 μm filter and 284 comprising a 1 μm filter are located by a filter retainer moulding 286 adjacent a top closure member or bulkhead 288 the filter members preventing any liquid or bacteria from being drawn out of the exhaust exit port 268 into the pump and aspiration path through to an exhaust and filter unit 290 which is connected to a casing outlet moulding at 291 via an exhaust tube (not shown) in casing side piece 236. The side pieces 236, 238 are provided with recesses 292 having support pins 294 therein to locate a carrying strap (not shown) for use by the patient. The side pieces 230 and canister 204 are also provided with features which prevent the canister and device from exhibiting a mutual “wobble” when connected together. Ribs (not shown) extending between the canister top closure member 288 and the inner face 300 of the upstanding flange 260 locate in grooves 302 in the device sidewalls when canister and device are connected. The casing 230 also houses all of the electrical equipment and control and power management features, the functioning of which was described briefly with respect to FIGS. 3 and 4 hereinabove. The side piece 238 is provided with a socket member 298 to receive a charging jack from an external mains powered battery charger (both not shown).



FIG. 10 shows a schematic cross section of a wound 400 and apparatus 402 connected thereto to apply TNP therapy to the wound and to measure its volume. The apparatus comprises wound filling material 404; an aspirant conduit 406 having one end 408 sealed within the wound cavity 410 by an overlying sealing drape 412 at point 414 and a distal end 416 of the conduit 406 attached to a waste canister 418 for the collection of exudate from the wound. The waste canister is operably connected to a pressure sensor 420 by a conduit portion 422 and to the inlet side of a vacuum pump 426 by a conduit portion 428. The vacuum pump output side is connected by a conduit portion 430 to a flow sensor 432 and exhaust is taken away via a conduit 434. A control and monitoring system is provided at 440 and receives signals 442 from the pressure sensor 420; receives signals 444 from the vacuum pump; and, receives signals 446 from the flow sensor 432. The control system 440 sends control signals 448 to the vacuum pump 426 in order for it to maintain a steady state pressure as set by instructions 450 entered by a clinician/user on a data entry keypad 452. The control system 440 outputs data 454 to a display 456 such as an LCD display, for example, as required by the clinician/user in response to instructions 450 but includes data relating to the volume of the wound 400. The sealing drape 412 is sealed to the patient's sound flesh at 460 surrounding the wound 400 generally by a layer of pressure sensitive adhesive (not shown) on the flesh contacting side of the drape 412.


In operation a clinician/user enters a required pressure, consistent with calibration procedures previously employed, to be achieved in the wound cavity 410 on the keypad 452. The vacuum pump 426 is initiated and pumps the wound cavity 410 down to the required pressure and continues to operate as appropriate to maintain the required pressure at a steady state. The apparatus 402 has been calibrated in that the volumes of the conduit 406; empty waste canister 418; conduits 422, 428, 430; and vacuum pump 426 are known and a correction factor has been entered in the memory of the control system 440.



FIG. 11 shows a graph of fluid flow, in this case air against time to achieve steady state conditions. FIG. 11 indicates time taken to reach a steady state pressure as set in the control system at start up and which time to reach a steady state pressure is indicated by the line 500. Initially the rate of air flow rises rapidly to a maximum at 502 after which the flow rate falls off as the set pressure is approached and the steady state is achieved at line 502. Part of the flow rate under the curve 504 may probably be due to an inward leak of air, most probably into the wound cavity 410 (the joints between the component parts of the apparatus from the conduit 406 in the direction of fluid flow should all be sound and leak-free) between the sealing drape 412 and the patient's sound flesh 460. The point 508 indicates the steady state flow rate to maintain the desired set pressure and the area of the triangle 510, 508, 512 indicates the portion or volume of air aspirated from the wound cavity attributable to the leak and may be deducted from the total area under the curve 504 up to the line 500. Thus, the control and monitoring system 440 computes the volume of the wound from the area under the curve 504 bounded by the line 508-510 and will be displayed on the display 456 and/or in suitable recording apparatus (not shown).


A similar graph to that of FIG. 11 and shown in FIG. 12 may be drawn but showing flow against pressure in the wound cavity 410. Steady state is reached when the set pressure has been achieved. In the graph of FIG. 12 the set pressure 600 and steady state coincide at the line 602 and the total area under the curve 604 is comprised of: a factor relating to leak rate as before and is the triangular area 600, 606, 608; a factor relating to system volume indicated by the vertically hatched area 610 and the wound volume indicated by the area 612. When the system is at a steady state indicated by the line 614 the flow through the flow sensor relates only to the leakage into the system.


The volume of the wound may be computed from the expression:







V
wound

=

Area





under





curve



×

(

760
-

Set





pressure





in





mmHg


)


760






If the dressing drape 412 is completely leak-free then the steady state flow rate when the set required pressure is reached will be zero and the point 508 will lie on the time axis.


The flow meter 432 is shown as situated after the vacuum pump 426 but may in other embodiments of apparatus according to the present invention lie between the waste canister 418 and the vacuum pump 426. Suitable correction factors relating to the exact arrangement of apparatus used will need to be determined.


The method of the present invention may be carried out by the apparatus described and discussed with reference to FIGS. 1 to 9 above which also constitutes apparatus according to the present invention.


Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, means “including but not limited to”, and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.


Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.


Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.

Claims
  • 1. A negative pressure wound therapy device comprising: a negative pressure source configured to be connected to a wound via a fluid flow path and to provide negative pressure to the wound; anda controller programmed to operate the negative pressure source, the controller further programmed to: monitor a cumulative fluid flow rate in the fluid flow path, the cumulative fluid flow rate comprising a first fluid flow rate due to operation of the negative pressure source and a second fluid flow rate due to a leak in the fluid flow path,determine the second fluid flow rate due to the leak in the fluid flow path,determine a volume of the wound based on the cumulative fluid flow rate and the second fluid flow rate due to the leak in the fluid flow path, andprovide an indication of the volume of the wound.
  • 2. The device of claim 1, wherein the controller is programmed to: provide an indication of the second fluid flow rate due to the leak.
  • 3. The device of claim 2, wherein the controller is programmed to: determine the second fluid flow rate responsive to the negative pressure source operating in a steady state.
  • 4. The device of claim 3, wherein in the steady state, the second fluid flow rate is equivalent to the cumulative fluid flow rate.
  • 5. The device of claim 3, further comprising a pressure sensor configured to measure pressure in the fluid flow path, wherein the steady state is determined based on the measured pressure.
  • 6. The device of claim 5, wherein the pressure sensor is configured to be positioned in the fluid flow path between the negative pressure source and a wound dressing covering the wound.
  • 7. The device of claim 1, further comprising a display configured to display information relating to the cumulative fluid flow rate.
  • 8. The device of claim 1, further comprising a flow sensor configured to monitor the cumulative fluid flow rate.
  • 9. The device of claim 8, wherein the flow sensor comprises a flow meter.
  • 10. The device of claim 1, wherein the controller is programmed to: determine and apply a correction factor to the cumulative fluid flow rate to determine the first fluid flow rate due to the operation of the negative pressure source.
  • 11. A kit comprising the device of claim 1 and a wound dressing configured to cover the wound.
  • 12. A non-transitory computer readable medium storing instructions that, when executed by a controller of a negative pressure wound therapy device, cause the controller to: via a fluid flow path, operate a negative pressure source to provide negative pressure to a wound covered by a wound dressing;measure a cumulative fluid flow rate, wherein the cumulative fluid flow rate comprises a first fluid flow rate due to operation of the negative pressure source and a second fluid flow rate due to a leak in the fluid flow path;determine the second fluid flow rate due to the leak in the fluid flow path;determine a volume of the wound based on the cumulative fluid flow rate and the second fluid flow rate due to the leak in the fluid flow path; andprovide an indication of the volume of the wound.
  • 13. The medium of claim 12, wherein the instructions further cause the controller to: determine and apply a correction factor to the cumulative fluid flow rate to determine the first fluid flow rate due to operation of the negative pressure source.
  • 14. The medium of claim 13, wherein the instructions further cause the controller to provide an indication of the cumulative fluid flow rate.
  • 15. The medium of claim 14, wherein the indication comprises a visual indication.
  • 16. The medium of claim 12, wherein the instructions further cause the controller to determine the second fluid flow rate responsive to the negative pressure source operating in a steady state.
  • 17. The medium of claim 16, wherein in the steady state, the second fluid flow rate is equivalent to the cumulative fluid flow rate.
  • 18. The medium of claim 16, wherein the steady state is determined based on monitoring pressure in the fluid flow path.
Priority Claims (1)
Number Date Country Kind
0723855 Dec 2007 GB national
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/994,818, filed on May 31, 2018, which is a continuation of U.S. patent application Ser. No. 14/946,468, filed on Nov. 19, 2015 and now U.S. Pat. No. 9,987,402, which is a continuation of U.S. patent application Ser. No. 14/455,200, filed Aug. 8, 2014 and now U.S. Pat. No. 9,192,332, which is a division of U.S. application Ser. No. 12/746,492, filed Jun. 4, 2010 and now U.S. Pat. No. 8,814,841, which is a U.S. national stage application of International Patent Application No. PCT/GB2008/050917, filed on Oct. 7, 2008, which claims the benefit of U.K. Application No. GB 0723855.3, filed on Dec. 6, 2007; the disclosure of each of which is hereby incorporated by reference in its entirety.

US Referenced Citations (440)
Number Name Date Kind
3572340 Lloyd et al. Mar 1971 A
3787882 Fillmore et al. Jan 1974 A
3972328 Chen Aug 1976 A
4015912 Kofink Apr 1977 A
4062012 Colbert et al. Dec 1977 A
4599052 Langen et al. Jul 1986 A
4643641 Clausen et al. Feb 1987 A
4710165 McNeil et al. Dec 1987 A
4969880 Zamierowski Nov 1990 A
5127388 Cicalese et al. Jul 1992 A
5173033 Adahan Dec 1992 A
5222714 Morinigo et al. Jun 1993 A
5238732 Krishnan Aug 1993 A
5291822 Alsobrooks et al. Mar 1994 A
5349896 Delaney, III et al. Sep 1994 A
5358494 Svedman Oct 1994 A
5360445 Goldowsky Nov 1994 A
5391179 Mezzoli Feb 1995 A
5417743 Dauber May 1995 A
5437651 Todd et al. Aug 1995 A
5449003 Sugimura Sep 1995 A
5449347 Preen et al. Sep 1995 A
5449584 Banba et al. Sep 1995 A
5466229 Elson et al. Nov 1995 A
5492313 Pan et al. Feb 1996 A
5549584 Gross Aug 1996 A
5616121 McKay Apr 1997 A
5634391 Eady Jun 1997 A
5636643 Argenta Jun 1997 A
5645081 Argenta et al. Jul 1997 A
5676525 Berner et al. Oct 1997 A
5685214 Neff et al. Nov 1997 A
5687633 Eady Nov 1997 A
5693013 Geuder Dec 1997 A
5730587 Snyder et al. Mar 1998 A
5743170 Pascual et al. Apr 1998 A
5759570 Arnold Jun 1998 A
5769608 Seale Jun 1998 A
5785508 Bolt Jul 1998 A
5827246 Bowen Oct 1998 A
5863184 Juterbock et al. Jan 1999 A
5897296 Yamamoto et al. Apr 1999 A
5950523 Reynolds Sep 1999 A
6056519 Morita et al. May 2000 A
6068588 Goldowsky May 2000 A
6071267 Zamierowski Jun 2000 A
6080685 Eady Jun 2000 A
6102680 Fraser et al. Aug 2000 A
6138550 Fingar, Jr. et al. Oct 2000 A
6142982 Hunt et al. Nov 2000 A
6145430 Able et al. Nov 2000 A
6158327 Huss Dec 2000 A
6162194 Shipp Dec 2000 A
6174136 Kilayko et al. Jan 2001 B1
6193658 Wendelken et al. Feb 2001 B1
6227825 Vay May 2001 B1
6230609 Bender et al. May 2001 B1
6231310 Tojo et al. May 2001 B1
6249198 Clark et al. Jun 2001 B1
6323568 Zabar Nov 2001 B1
6327960 Heimueller et al. Dec 2001 B1
6343539 Du Feb 2002 B1
6413057 Hong et al. Jul 2002 B1
6514047 Burr et al. Feb 2003 B2
6540490 Lilie Apr 2003 B1
6589028 Eckerbom et al. Jul 2003 B1
6604908 Bryant et al. Aug 2003 B1
6618221 Gillis et al. Sep 2003 B2
6623255 Joong et al. Sep 2003 B2
6626891 Ohmstede Sep 2003 B2
6638035 Puff Oct 2003 B1
6652252 Zabar Nov 2003 B2
6655257 Meyer Dec 2003 B1
6673036 Britto Jan 2004 B1
6685681 Lockwood et al. Feb 2004 B2
6695823 Lina et al. Feb 2004 B1
6752794 Lockwood et al. Jun 2004 B2
6755807 Risk, Jr. et al. Jun 2004 B2
6756903 Omry et al. Jun 2004 B2
6815846 Godkin Nov 2004 B2
6823905 Smith et al. Nov 2004 B1
6877419 Ohrle et al. Apr 2005 B2
6936037 Bubb et al. Aug 2005 B2
6951553 Bubb et al. Oct 2005 B2
6979324 Bybordi et al. Dec 2005 B2
7022113 Lockwood et al. Apr 2006 B2
7041057 Faupel et al. May 2006 B1
7108683 Zamierowski Sep 2006 B2
7128735 Weston Oct 2006 B2
7151348 Ueda et al. Dec 2006 B1
7198046 Argenta Apr 2007 B1
7361184 Joshi Apr 2008 B2
7363850 Becker Apr 2008 B2
7374409 Kawamura May 2008 B2
7381859 Hunt et al. Jun 2008 B2
7401703 McMichael et al. Jul 2008 B2
7447327 Kitamura et al. Nov 2008 B2
7524315 Blott et al. Apr 2009 B2
7534927 Lockwood et al. May 2009 B2
7550034 Janse Van Rensburg et al. Jun 2009 B2
7553306 Hunt et al. Jun 2009 B1
7569742 Haggstrom et al. Aug 2009 B2
7615036 Joshi et al. Nov 2009 B2
7625362 Boehringer et al. Dec 2009 B2
7670323 Hunt et al. Mar 2010 B2
7699823 Haggstrom et al. Apr 2010 B2
7700819 Ambrosio et al. Apr 2010 B2
7708724 Weston May 2010 B2
7722582 Lina et al. May 2010 B2
7758555 Kelch et al. Jul 2010 B2
7759537 Bishop et al. Jul 2010 B2
7759539 Shaw et al. Jul 2010 B2
7775998 Riesinger Aug 2010 B2
7779625 Joshi et al. Aug 2010 B2
7785247 Tatum et al. Aug 2010 B2
7811269 Boynton et al. Oct 2010 B2
7838717 Haggstrom et al. Nov 2010 B2
7846141 Weston Dec 2010 B2
7909805 Weston Mar 2011 B2
7910791 Coffey Mar 2011 B2
7922703 Riesinger Apr 2011 B2
7927319 Lawhorn Apr 2011 B2
7964766 Blott et al. Jun 2011 B2
8007257 Heaton et al. Aug 2011 B2
8025052 Matthews et al. Sep 2011 B2
8034037 Adams et al. Oct 2011 B2
8061360 Locke et al. Nov 2011 B2
8062272 Weston Nov 2011 B2
8062273 Weston Nov 2011 B2
8062331 Zamierowski Nov 2011 B2
8080702 Blott et al. Dec 2011 B2
8097272 Addison Jan 2012 B2
8105295 Blott et al. Jan 2012 B2
8118794 Weston Feb 2012 B2
8152785 Vitaris Apr 2012 B2
8162907 Heagle Apr 2012 B2
8186978 Tinholt et al. May 2012 B2
8188331 Barta et al. May 2012 B2
8202262 Lina et al. Jun 2012 B2
8207392 Haggstrom et al. Jun 2012 B2
8215929 Shen et al. Jul 2012 B2
8241015 Lillie et al. Aug 2012 B2
8241018 Harr Aug 2012 B2
8241261 Randolph et al. Aug 2012 B2
8257327 Blott et al. Sep 2012 B2
8257328 Augustine et al. Sep 2012 B2
8267918 Johnson et al. Sep 2012 B2
8282611 Weston Oct 2012 B2
8294586 Pidgeon et al. Oct 2012 B2
8303552 Weston Nov 2012 B2
8308714 Weston et al. Nov 2012 B2
8317774 Adahan Nov 2012 B2
8323264 Weston et al. Dec 2012 B2
8350116 Lockwood et al. Jan 2013 B2
8363881 Godkin Jan 2013 B2
8366690 Locke et al. Feb 2013 B2
8366692 Weston et al. Feb 2013 B2
8372049 Jaeb et al. Feb 2013 B2
8372050 Jaeb et al. Feb 2013 B2
8398614 Blott et al. Mar 2013 B2
D679819 Peron Apr 2013 S
D679820 Peron Apr 2013 S
8409157 Haggstrom et al. Apr 2013 B2
8409170 Locke et al. Apr 2013 B2
8414519 Hudspeth et al. Apr 2013 B2
8425478 Olson Apr 2013 B2
8444612 Patel et al. May 2013 B2
8449267 Pascual et al. May 2013 B2
8449509 Weston May 2013 B2
8460255 Joshi et al. Jun 2013 B2
8545464 Weston Oct 2013 B2
8569566 Blott et al. Oct 2013 B2
8617129 Hartwell Dec 2013 B2
8622981 Hartwell et al. Jan 2014 B2
8628505 Weston Jan 2014 B2
8641691 Fink et al. Feb 2014 B2
8663198 Buan et al. Mar 2014 B2
8663200 Weston et al. Mar 2014 B2
8715256 Greener May 2014 B2
8734131 McCrone et al. May 2014 B2
8734425 Nicolini May 2014 B2
8764732 Hartwell Jul 2014 B2
8795243 Weston Aug 2014 B2
8808274 Hartwell Aug 2014 B2
8814841 Hartwell Aug 2014 B2
8827983 Braga et al. Sep 2014 B2
8829263 Haggstrom et al. Sep 2014 B2
8834451 Blott et al. Sep 2014 B2
8843327 Vernon-Harcourt et al. Sep 2014 B2
8845603 Middleton et al. Sep 2014 B2
8905985 Allen et al. Dec 2014 B2
8945074 Buan et al. Feb 2015 B2
8951235 Allen et al. Feb 2015 B2
8956336 Haggstrom et al. Feb 2015 B2
8974429 Gordon et al. Mar 2015 B2
9061095 Adie et al. Jun 2015 B2
9067003 Buan et al. Jun 2015 B2
9084845 Adie et al. Jul 2015 B2
9192332 Hartwell Nov 2015 B2
9199011 Locke et al. Dec 2015 B2
9199012 Vitaris et al. Dec 2015 B2
9220822 Hartwell Dec 2015 B2
9220823 Nicolini Dec 2015 B2
9312557 Zhang et al. Apr 2016 B2
9314557 Ricci et al. Apr 2016 B2
9987402 Hartwell Jun 2018 B2
20010001278 Drevet May 2001 A1
20010033795 Humpheries Oct 2001 A1
20010043870 Song Nov 2001 A1
20020026946 McKay Mar 2002 A1
20020122732 Oh et al. Sep 2002 A1
20020164255 Burr et al. Nov 2002 A1
20020198504 Risk, Jr. et al. Dec 2002 A1
20030035743 Lee et al. Feb 2003 A1
20030040687 Boynton et al. Feb 2003 A1
20030095879 Oh et al. May 2003 A1
20030099558 Chang May 2003 A1
20030108430 Yoshida et al. Jun 2003 A1
20030110939 Able et al. Jun 2003 A1
20030133812 Puff et al. Jul 2003 A1
20030161735 Kim et al. Aug 2003 A1
20030162071 Yasuda Aug 2003 A1
20030175125 Kwon et al. Sep 2003 A1
20030175135 Heo et al. Sep 2003 A1
20030230191 Ohrle et al. Dec 2003 A1
20040005222 Yoshida et al. Jan 2004 A1
20040021123 Howell et al. Feb 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20040066097 Kobayashi et al. Apr 2004 A1
20040071568 Hyeon Apr 2004 A1
20040071572 Greter Apr 2004 A1
20040115076 Lilie et al. Jun 2004 A1
20040118460 Stinson Jun 2004 A1
20040126250 Tsuchiya et al. Jul 2004 A1
20040155741 Godin Aug 2004 A1
20040156730 Lilie et al. Aug 2004 A1
20040163713 Schulze et al. Aug 2004 A1
20040182237 Headley et al. Sep 2004 A1
20040189103 Duncan et al. Sep 2004 A1
20040219059 Barringer et al. Nov 2004 A1
20050031470 Lee Feb 2005 A1
20050098031 Yoon et al. May 2005 A1
20050100450 Bryant et al. May 2005 A1
20050110190 Giardini et al. May 2005 A1
20050111987 Yoo et al. May 2005 A1
20050123422 Lilie Jun 2005 A1
20050124966 Karpowicz et al. Jun 2005 A1
20050129540 Puff Jun 2005 A1
20050135946 Kang et al. Jun 2005 A1
20050142007 Lee et al. Jun 2005 A1
20050142008 Jung et al. Jun 2005 A1
20050155657 Kach et al. Jul 2005 A1
20050163635 Berwanger et al. Jul 2005 A1
20050209560 Boukhny et al. Sep 2005 A1
20050251117 Anderson et al. Nov 2005 A1
20050267402 Stewart et al. Dec 2005 A1
20050271526 Chang et al. Dec 2005 A1
20050272142 Horita Dec 2005 A1
20050276706 Radue Dec 2005 A1
20060009744 Erdman et al. Jan 2006 A1
20060017332 Kang et al. Jan 2006 A1
20060018771 Song et al. Jan 2006 A1
20060019144 Hidaka et al. Jan 2006 A1
20060024181 Kim Feb 2006 A1
20060029675 Ginther Feb 2006 A1
20060039806 Becker Feb 2006 A1
20060056979 Yoo et al. Mar 2006 A1
20060056980 Yoo et al. Mar 2006 A1
20060057000 Hyeon Mar 2006 A1
20060061024 Jung et al. Mar 2006 A1
20060073036 Pascual et al. Apr 2006 A1
20060083623 Higgins et al. Apr 2006 A1
20060110259 Puff et al. May 2006 A1
20060118190 Takehana et al. Jun 2006 A1
20060122558 Sherman et al. Jun 2006 A1
20060191575 Naesje Aug 2006 A1
20060192259 Silverbrook Aug 2006 A1
20060210411 Hyeon Sep 2006 A1
20060216165 Lee Sep 2006 A1
20060222532 Lee et al. Oct 2006 A1
20060228224 Hong et al. Oct 2006 A1
20060245947 Seto et al. Nov 2006 A1
20060251523 Lee et al. Nov 2006 A1
20060271020 Huang et al. Nov 2006 A1
20060282174 Haines Dec 2006 A1
20060282175 Haines et al. Dec 2006 A1
20060287632 Sarangapani Dec 2006 A1
20070014837 Johnson et al. Jan 2007 A1
20070016152 Karpowicz et al. Jan 2007 A1
20070032741 Hibner et al. Feb 2007 A1
20070032762 Vogel Feb 2007 A1
20070032763 Vogel Feb 2007 A1
20070040454 Freudenberger et al. Feb 2007 A1
20070041856 Hansen et al. Feb 2007 A1
20070052144 Knirck et al. Mar 2007 A1
20070055209 Patel et al. Mar 2007 A1
20070078444 Larsson Apr 2007 A1
20070091614 Kaisser et al. Apr 2007 A1
20070179460 Adahan Aug 2007 A1
20070196214 Bocchiola Aug 2007 A1
20070219532 Karpowicz et al. Sep 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070256428 Unger et al. Nov 2007 A1
20070260226 Jaeb et al. Nov 2007 A1
20070276195 Xu et al. Nov 2007 A1
20070276309 Xu et al. Nov 2007 A1
20070282283 Kaern et al. Dec 2007 A1
20070292286 Hell et al. Dec 2007 A1
20070295201 Dadd Dec 2007 A1
20080004549 Anderson Jan 2008 A1
20080008607 Schade et al. Jan 2008 A1
20080015526 Reiner et al. Jan 2008 A1
20080020178 Ohrle et al. Jan 2008 A1
20080051708 Kumar et al. Feb 2008 A1
20080071161 Jaeb et al. Mar 2008 A1
20080071162 Jaeb Mar 2008 A1
20080071216 Locke et al. Mar 2008 A1
20080082040 Kubler et al. Apr 2008 A1
20080089796 Schade et al. Apr 2008 A1
20080094753 Brodkin et al. Apr 2008 A1
20080110336 Cresswell et al. May 2008 A1
20080125697 Gao May 2008 A1
20080125698 Gerg et al. May 2008 A1
20080191399 Chang Aug 2008 A1
20080208147 Argenta Aug 2008 A1
20080211435 Imagawa Sep 2008 A1
20080228526 Locke Sep 2008 A1
20080240942 Heinrich et al. Oct 2008 A1
20080260551 Simmons Oct 2008 A1
20080267797 Hell et al. Oct 2008 A1
20080281281 Meyer et al. Nov 2008 A1
20080306456 Riesinger Dec 2008 A1
20080310980 Ramsdorf et al. Dec 2008 A1
20090008306 Cicchello et al. Jan 2009 A1
20090012441 Mulligan Jan 2009 A1
20090012483 Blott Jan 2009 A1
20090012501 Boehringer Jan 2009 A1
20090028733 Duwel Jan 2009 A1
20090030383 Larsen et al. Jan 2009 A1
20090030402 Adahan Jan 2009 A1
20090053081 Griffiths Feb 2009 A1
20090054855 Blott Feb 2009 A1
20090060750 Chen et al. Mar 2009 A1
20090071551 Chalich Mar 2009 A1
20090081049 Tian et al. Mar 2009 A1
20090087323 Blakey et al. Apr 2009 A1
20090114293 Kanai et al. May 2009 A1
20090116712 Al-Moosawi et al. May 2009 A1
20090123513 Greener May 2009 A1
20090125004 Shen et al. May 2009 A1
20090129955 Schubert May 2009 A1
20090129986 Wimberger-Friedl et al. May 2009 A1
20090148320 Lucas Jun 2009 A1
20090149821 Scherson et al. Jun 2009 A1
20090157016 Adahan Jun 2009 A1
20090166411 Kramer et al. Jul 2009 A1
20090169402 Stenberg Jul 2009 A1
20090177051 Arons et al. Jul 2009 A1
20090206778 Roh et al. Aug 2009 A1
20090227969 Jaeb et al. Sep 2009 A1
20090234306 Vitaris Sep 2009 A1
20090270833 DeBelser et al. Oct 2009 A1
20090292264 Hudspeth et al. Nov 2009 A1
20090299251 Buan Dec 2009 A1
20090299306 Buan Dec 2009 A1
20090304534 Richter Dec 2009 A1
20090306580 Blott Dec 2009 A1
20090312723 Blott et al. Dec 2009 A1
20090312725 Braga Dec 2009 A1
20090315684 Sacco et al. Dec 2009 A1
20100030132 Niezgoda Feb 2010 A1
20100036367 Krohn Feb 2010 A1
20100042059 Pratt et al. Feb 2010 A1
20100068820 Meathrel et al. Mar 2010 A1
20100098566 Kang Apr 2010 A1
20100125258 Coulthard et al. May 2010 A1
20100126484 Skell et al. May 2010 A1
20100191126 Al-Moosawi et al. Jul 2010 A1
20100211030 Turner et al. Aug 2010 A1
20100244780 Turner et al. Sep 2010 A1
20100249733 Blott et al. Sep 2010 A9
20100265649 Singh et al. Oct 2010 A1
20100268179 Kelch et al. Oct 2010 A1
20100280435 Raney et al. Nov 2010 A1
20100305526 Robinson et al. Dec 2010 A1
20100324510 Andresen et al. Dec 2010 A1
20110000069 Ramsdorf et al. Jan 2011 A1
20110004172 Eckstein et al. Jan 2011 A1
20110020588 Shimizu et al. Jan 2011 A1
20110028921 Hartwell et al. Feb 2011 A1
20110054423 Blott et al. Mar 2011 A1
20110077605 Karpowicz et al. Mar 2011 A1
20110081267 McCrone et al. Apr 2011 A1
20110098600 Matsumura et al. Apr 2011 A1
20110103984 Santa May 2011 A1
20110118683 Weston May 2011 A1
20110130712 Topaz Jun 2011 A1
20110171044 Flanigan Jul 2011 A1
20110176945 Drevet Jul 2011 A1
20110176946 Drevet Jul 2011 A1
20110184341 Baker et al. Jul 2011 A1
20110202220 Seta et al. Aug 2011 A1
20110224631 Simmons et al. Sep 2011 A1
20110229352 Timmer Sep 2011 A1
20110236265 Hasui et al. Sep 2011 A1
20110236277 Lee et al. Sep 2011 A1
20110251569 Turner et al. Oct 2011 A1
20110257572 Locke et al. Oct 2011 A1
20110282310 Boehringer Nov 2011 A1
20120035469 Whelan et al. Feb 2012 A1
20120041399 Blott et al. Feb 2012 A1
20120259299 Ryu et al. Oct 2012 A1
20120271256 Locke et al. Oct 2012 A1
20130085462 Nip et al. Apr 2013 A1
20130090613 Kelch et al. Apr 2013 A1
20130116635 Fleischmann May 2013 A1
20130123755 Locke et al. May 2013 A1
20130138054 Fleischmann May 2013 A1
20130144230 Wu et al. Jun 2013 A1
20130144235 Augustine et al. Jun 2013 A1
20130150813 Gordon et al. Jun 2013 A1
20130150814 Buan Jun 2013 A1
20130165878 Heagle Jun 2013 A1
20130267917 Pan et al. Oct 2013 A1
20130274688 Weston Oct 2013 A1
20130331822 Patel et al. Dec 2013 A1
20140114268 Auguste et al. Apr 2014 A1
20140163490 Locke et al. Jun 2014 A1
20140163493 Weston et al. Jun 2014 A1
20140228791 Hartwell Aug 2014 A1
20140276487 Locke et al. Sep 2014 A1
20140316359 Collinson et al. Oct 2014 A1
20150025482 Begin et al. Jan 2015 A1
20150032035 Banwell et al. Jan 2015 A1
20150051560 Askem Feb 2015 A1
20150073363 Kelch et al. Mar 2015 A1
20150174304 Askem et al. Jun 2015 A1
20150217032 Allen et al. Aug 2015 A1
20160166741 Nicolini Jun 2016 A1
20200171217 Braga et al. Jun 2020 A9
Foreign Referenced Citations (181)
Number Date Country
101378795 Mar 2009 CN
101385887 Mar 2009 CN
101516431 Aug 2009 CN
101616700 Dec 2009 CN
101676563 Mar 2010 CN
201953601 Aug 2011 CN
103221077 Jul 2013 CN
102005007016 Aug 2006 DE
0208395 Jan 1987 EP
0411564 Feb 1991 EP
0578999 Jan 1994 EP
0604953 Jul 1994 EP
0759521 Feb 1997 EP
0775825 May 1997 EP
0793019 Sep 1997 EP
0809028 Nov 1997 EP
0898076 Feb 1999 EP
1114933 Jul 2001 EP
1153218 Nov 2001 EP
0909895 Dec 2002 EP
0708620 May 2003 EP
0993317 Sep 2003 EP
1406020 Apr 2004 EP
1430588 Jun 2004 EP
1449971 Aug 2004 EP
1476217 Nov 2004 EP
1554737 Jul 2005 EP
1556942 Jul 2005 EP
1469580 Dec 2005 EP
1757809 Feb 2007 EP
1850005 Oct 2007 EP
1460270 Jun 2008 EP
1791579 Jul 2009 EP
2145636 Jan 2010 EP
2161448 Mar 2010 EP
1932481 Jun 2010 EP
2216573 Aug 2010 EP
2253353 Nov 2010 EP
2302127 Mar 2011 EP
1956242 Apr 2011 EP
2366721 Sep 2011 EP
2462908 Jun 2012 EP
2544642 Jan 2015 EP
2648668 Jan 2015 EP
2836711 Feb 2015 EP
2109472 Aug 2015 EP
2254612 Oct 2019 EP
1163907 Oct 1958 FR
1039145 Aug 1966 GB
1220857 Jan 1971 GB
2235877 Mar 1991 GB
2273133 Jun 1994 GB
2306580 May 1997 GB
2342584 Apr 2000 GB
2418738 Apr 2006 GB
2433298 Jun 2007 GB
2000105011 Apr 2000 JP
2000220570 Aug 2000 JP
2000300662 Oct 2000 JP
2001241382 Sep 2001 JP
2001286807 Oct 2001 JP
2006233925 Sep 2006 JP
2008183244 Aug 2008 JP
2008194294 Aug 2008 JP
2010185458 Aug 2010 JP
2013514871 May 2013 JP
WO-8707683 Dec 1987 WO
WO-9420041 Sep 1994 WO
WO-9421312 Sep 1994 WO
WO-9605873 Feb 1996 WO
WO-9819068 May 1998 WO
WO-0000743 Jan 2000 WO
WO-0007653 Feb 2000 WO
WO-0021586 Apr 2000 WO
WO-0022298 Apr 2000 WO
WO-0049968 Aug 2000 WO
WO-0056378 Sep 2000 WO
WO-0061206 Oct 2000 WO
WO-0079154 Dec 2000 WO
WO-0116488 Mar 2001 WO
WO-0137922 May 2001 WO
WO-0179693 Oct 2001 WO
WO-02087058 Oct 2002 WO
WO-02090772 Nov 2002 WO
WO-03005943 Jan 2003 WO
WO-03057307 Jul 2003 WO
WO-03085810 Oct 2003 WO
WO-03099356 Dec 2003 WO
WO-03101508 Dec 2003 WO
WO-2004007960 Jan 2004 WO
WO-2004037334 May 2004 WO
WO-2004081421 Sep 2004 WO
WO-2005001287 Jan 2005 WO
WO-2005009488 Feb 2005 WO
WO-2005046760 May 2005 WO
WO-2005046761 May 2005 WO
WO-2005046762 May 2005 WO
WO-2005105180 Nov 2005 WO
WO-2005123170 Dec 2005 WO
WO-2006046060 May 2006 WO
WO-2006052745 May 2006 WO
WO-2006052839 May 2006 WO
WO-2006058801 Jun 2006 WO
WO-2006059098 Jun 2006 WO
WO-2006062276 Jun 2006 WO
WO-2006069875 Jul 2006 WO
WO-2006069884 Jul 2006 WO
WO-2006069885 Jul 2006 WO
WO-2006092333 Sep 2006 WO
WO-2006111775 Oct 2006 WO
WO-2006117207 Nov 2006 WO
WO-2006122268 Nov 2006 WO
WO-2007019038 Feb 2007 WO
WO-2007049876 May 2007 WO
WO-2007055642 May 2007 WO
WO-2007067359 Jun 2007 WO
WO-2007087811 Aug 2007 WO
WO-2007092397 Aug 2007 WO
WO-2007113597 Oct 2007 WO
WO-2008013896 Jan 2008 WO
WO-2008027449 Mar 2008 WO
WO-2008031418 Mar 2008 WO
WO-2008036345 Mar 2008 WO
WO-2008039223 Apr 2008 WO
WO-2008039314 Apr 2008 WO
WO-2008048481 Apr 2008 WO
WO-2008049029 Apr 2008 WO
WO-2008100440 Aug 2008 WO
WO-2008110022 Sep 2008 WO
WO-2008135997 Nov 2008 WO
WO-2008154158 Dec 2008 WO
WO-2009019415 Feb 2009 WO
WO-2009047524 Apr 2009 WO
WO-2009066104 May 2009 WO
WO-2009066105 May 2009 WO
WO-2009071924 Jun 2009 WO
WO-2009089390 Jul 2009 WO
WO-2009095170 Aug 2009 WO
WO-2009103031 Aug 2009 WO
WO-2009124100 Oct 2009 WO
WO-2009124125 Oct 2009 WO
WO-2009126103 Oct 2009 WO
WO-2009146441 Dec 2009 WO
WO-2009151645 Dec 2009 WO
WO-2009156984 Dec 2009 WO
WO-2009158128 Dec 2009 WO
WO-2010017484 Feb 2010 WO
WO-2010021783 Feb 2010 WO
WO-2010033613 Mar 2010 WO
WO-2010033769 Mar 2010 WO
WO-2010039481 Apr 2010 WO
WO-2010051068 May 2010 WO
WO-2010051418 May 2010 WO
WO-2010072349 Jul 2010 WO
WO-2010093753 Aug 2010 WO
WO-2010126444 Nov 2010 WO
WO-2010142959 Dec 2010 WO
WO-2010147533 Dec 2010 WO
WO-2011087871 Oct 2011 WO
WO-2011135285 Nov 2011 WO
WO-2011135286 Nov 2011 WO
WO-2011135287 Nov 2011 WO
WO-2011144888 Nov 2011 WO
WO-2012038724 Mar 2012 WO
WO-2012131237 Oct 2012 WO
WO-2012140378 Oct 2012 WO
WO-2012143665 Oct 2012 WO
WO-2013010907 Jan 2013 WO
WO-2013064852 May 2013 WO
WO-2013083800 Jun 2013 WO
WO-2013118447 Aug 2013 WO
WO-2013140255 Sep 2013 WO
WO-2013149078 Oct 2013 WO
WO-2014008348 Jan 2014 WO
WO-2014016759 Jan 2014 WO
WO-2014020440 Feb 2014 WO
WO-2014020443 Feb 2014 WO
WO-2014108476 Jul 2014 WO
WO-2014113253 Jul 2014 WO
WO-2015022334 Feb 2015 WO
WO-2015022340 Feb 2015 WO
Non-Patent Literature Citations (97)
Entry
Annex to the Communication, re the Opposition of European Patent No. EP 2237724, dated Oct. 30, 2017, 15 pages.
Annex to the Communication, the Opposition of European Patent No. 2773383, mailed on Sep. 13, 2019, 17 pages.
Appeal Decision for Japanese Patent Application No. 2013528768, mailed on Jul. 14, 2017, 20 pages.
Brief Communication—Letter from the Opponent, re the Opposition of European Patent No. 2773383, dated Mar. 24, 2021, 4 pages.
Brief Communication—Letter from the Proprietor of the Patent, re the Opposition of European Patent No. 2773383, dated Mar. 24, 2021, 25 pages.
Brief Communication, Letter from the Proprietor for Opposition of European Patent No. EP 2237724, mailed on Jun. 19, 2017, 24 pages.
Brief Communication, Letter from the Proprietor for Opposition of European Patent No. EP2237724, mailed on Aug. 21, 2018, 5 pages.
Brief Communication of the Opposition Proceedings for European Patent No. 3326656, mailed on Aug. 25, 2021, 34 pages.
British Standards Institution, “Sterilization of medical devices and packaging,” retrieved from URL: https://shop.bsigroup.com/en/Browse-By-Subject/Medical-Device-Standards/Sterilization-of-medical-devices-and-packaging/ on Mar. 12, 2020, 1 page.
Communication of further notices of opposition pursuant to Rule 79(2) EPC for the European Patent No. 3146986, mailed on Aug. 20, 2020, 2 pages.
Consolidated List of Cited Opposition Documents of the European Patent No. 2773383, dated Jan. 23, 2020, 1 page.
Decision to Maintain the European Patent in Amended Form (Art, 101 (3)(a) EPC) for European Patent No. 2237724, mailed on Sep. 19, 2019, 2 pages.
Diels K., et al., “Leybold Vacuum Handbook,” Pergamon Press, 1966, 10 pages.
Extent of the Opposition and Request for European Patent No. 3326656, mailed on Feb. 12, 2021, 58 pages.
Grounds for the Decision and Annex to the Communication, Opposition of European Patent No. 2237724, dated Jan. 7, 2019, 78 pages.
Information about the result of oral proceedings for European Patent No. 2773383, dated May 19, 2021, 2 pages.
International Preliminary Report on Patentability for Application No. PCT/GB2008/050917, mailed on Jun. 8, 2010, 7 pages.
International Preliminary Report on Patentability for Application No. PCT/GB2011/051745, mailed on Mar. 26, 2013, 7 pages.
International Preliminary Report on Patentability re PCT Application No. PCT/US2011/059016 dated Apr. 29, 2014, 12 pages.
International Search Report and Written Opinion for Application No. PCT/IB2011/002943, mailed on Jan. 28, 2013, 24 pages.
International Search Report and Written Opinion for Application No. PCT/US2011/059016, mailed on Apr. 23, 2014, 20 pages.
International Search Report for Application No. PCT/GB2008/050917, mailed on Jan. 14, 2009, 4 pages.
International Search Report for Application No. PCT/GB2011/051745, mailed on Feb. 2, 2012, 5 pages.
Invitation to Pay Additional Fees and Partial Search Report for Application No. PCT/US2011/059016, mailed on Feb. 17, 2014, 7 pages.
KCI, Inc., “Acti V.A.C. Therapy System,” User Manual, Sep. 2007, 64 pages.
KCI Licensing, Inc., “V.A.C. Via™—Negative Pressure Wound Therapy System,” 7-Day V.A.C.® Therapy System, Instructions for Use, 360063 Rev B, Aug. 2010, 24 pages.
KCI USA Inc., “SNAP™ Therapy System,” Instructions for Use, SNAP™ Therapy Cartridge, Jul. 2016, 2 pages.
Kendall ULTEC Hydrocolloid Dressing (4x4″), Product Ordering Page, web page downloaded on Jul. 13, 2014, 1 page.
Letter relating to the Appeal Procedure for the Opposition of the European Patent No. 2618860, mailed on Dec. 23, 2019, 5 pages.
Martin L.H., et al., “A Manual of Vacuum Practice,” Melbourne University Press, first published 1947, reprinted 1948, 12 pages.
Matsunaga K., et al., “Gas Permeability of Thermoplastic Polyurethane Elastomers,” Polymer Journal, Jun. 2005, vol. 37, No. 6, pp. 413-417.
Morcos A.C., “Voice Coil Actuators & Their Use in Advanced Motion Control Systems,” Motion, Jul./Aug. 1995, pp. 25-27.
“SNAP™—Wound Care System,” Instructions for Use (L20897), Dec. 9, 2007, 16 pages.
Notice of Communication of amended entries concerning the representative (R. 143(1)(h) EPC) and enclosed letter from the proprietor of the patent dated Jan. 8, 2021 for the European Patent No. 3146986, mailed on Jan. 20, 2021, 6 pages.
Notice of Opposition—Statement of Facts and Arguments for the European Patent No. 2618860, mailed on Aug. 26, 2016, 9 pages.
Notice of Opposition—Statement of Facts and Evidence for the European Patent No. 2773383, dated Dec. 28, 2018, 20 pages.
Notice of Opposition—Statement of Facts and Evidence of the European Patent No. 2237724, dated Dec. 30, 2016, 15 pages.
Notice of Opposition to a European Patent No. 2618860, dated Mar. 16, 2016, 5 pages.
Observations filed by Third Party for the European Patent No. 2773383, mailed on Jan. 28, 2020, 7 pages.
Opponent Arguments for the European Patent No. EP2773383, dated Jan. 28, 2020, 25 pages.
Opponent's Statement of Facts and Arguments for the European Patent No. 3146986, mailed on Jul. 30, 2020, 6 pages.
Opponent Submissions Prior to Oral Proceedings for Opposition to European Patent No. 2618860, dated Sep. 14, 2017, 4 pages.
Opponent's Written Submission in Preparation for the Oral Proceedings, opposition of the European Patent No. 2773383, dated Mar. 16, 2020, 8 pages.
Opponent's Written Submission in Preparation for the Oral Proceedings, Opposition of the European Patent No. 2237724, dated Aug. 10, 2018, 14 pages.
Opposition—Statement of Facts and Evidence for Opposition for the European Patent No. 2618860, filed on Mar. 16, 2016, 9 pages.
Opposition by KCI Licensing Inc. to EP2708216 Smith & Nephew Inc., Submitted as Evidence in Support of tile Appeal re European Patent No. 2618860, dated Apr. 5, 2018, 5 pages.
Oral Proceeding Minutes, Decision Rejecting the Opposition, and Grounds of Decision, re European Patent No. EP2618860, dated Jan. 19, 2018, 11 pages.
Park S.M., et al., “Design and Analysis of VCA for Fuel Pump in Automobile,” World of Academy of Science, Engineering and Technology, vol. 80, 2011, pp. 573-576.
Patentee Final Written Submissions in Advance of Oral Proceedings for Opposition to European Patent No. 2618860, dated Sep. 13, 2017, 4 pages.
Preliminary Opinion of the Opposition Division for the European Patent No. 2618860, mailed on Dec. 22, 2016, 5 pages.
Proprietor Arguments for the European Patent No. EP2773383, dated Jan. 28, 2020, 32 pages.
Proprietor Reply to Statement of Opponent's Grounds of Appeal, re European Patent No. 2618860, dated Sep. 28, 2018, 38 pages.
Proprietor's Written Submission in Preparation for the Oral Proceedings, opposition of European Patent No. 2773383, dated Mar. 18, 2020, 9 pages.
Protz K., “Modern Wound Dressings Support the Healing Process,” Wound care: Indications and Application, Geriatrie Journal, Apr. 2005, pp. 3333-3339 (17 pages with English translation).
Rangwala A.S., “Reciprocating Machinery Dynamics,” New Age International Publishers, ISBN:81-224-1813-9, 2006, 6 pages.
Reply of the Patent Proprietor to the Notice of the Opposition, the Opposition of European Patent No. 2773383, mailed on Jun. 3, 2019, 11 pages.
Reply of the Patent Proprietor to the Notice(s) of Opposition for European Patent No. EP2237724, dated May 31, 2017, 9 pages.
SNAP™ Therapy System, “Monograph,” KCI, 3 pages.
Statement of Opponent's Grounds of Appeal for European Patent No. EP2618860, dated May 18, 2018, 4 pages.
Summons to attend oral proceedings pursuant to Rule 115(1) EPC for European Patent No. 2773383, mailed on Sep. 30, 2020, 19 pages.
Summons to attend oral proceedings pursuant to Rule 115(1) EPC for the European Patent No. 3146986, mailed on Apr. 19, 2021, 10 pages.
Termination of the Opposition Proceedings with Maintenance for European Patent No. 2237724, mailed on Sep. 13, 2019, 1 page.
The Constructor, “Reciprocating Pump—Components, Working and Uses,” Retrieved from https://theconstructor.org/practical-guide/reciprocating-pumpcomponents-working-uses/2914/ on Jan. 21, 2020, 4 pages.
The Free Dictionary, “Volume,” The American Heritage Dictionary of the English Language, Retrieved from http://www.thefreedictionary.com/volume, Fourth Edition, 2000, 3 pages.
Wikipedia, “Pump,” retrieved from https://en.wikipedia.org/wiki/Pump on Mar. 13, 2020, 11 pages.
Written Submission by the Opponent for Opposition of European Patent No. EP2773383, dated Jul. 22, 2020, 2 pages.
Written Submission by the Proprietor for Opposition of European Patent No. EP2773383, dated Jul. 22, 2020, 15 pages.
Board of Appeal—Letter of the opponent dated May 26, 2023 for European Patent No. 3326656, mailed on Jun. 1, 2023, 60 pages.
Board of Appeal—Letter of the Patent Proprietor dated Dec. 7, 2022 for European Patent No. 2773383, mailed on Dec. 13, 2022, 6 pages.
Brief Communication—Letter from the opponent of the Patent, re the Opposition for European Patent No. 3146986, dated Feb. 3, 2022, 2 pages.
Brief Communication—Letter from the opponent of the Patent, re the Opposition for European Patent No. 3146986, dated Jan. 26, 2022, 4 pages.
Brief Communication—Letter from the Opponent, re the Opposition of European Patent No. 3326656, dated Oct. 14, 2021, 41 pages.
Brief Communication—Letter from the Opposition Division Aug. 29, 2022, for European Patent No. 3326656, mailed on Aug. 29, 2022, 2 pages.
Brief Communication—Letter from the Proprietor of the Patent, re the Opposition for European Patent No. 3146986, dated Dec. 15, 2021, 7 pages.
Brief Communication—Letter from the Proprietor of the Patent, re the Opposition for Simmons & Simmons for European Patent No. 3146986, dated Feb. 7, 2022, 2 pages.
Brief Communication—Letter of the Opponent of Aug. 19, 2022, for European Patent No. 3326656, mailed on Aug. 24, 2022, 26 pages.
Brief Communication of the Opposition Proceedings for European Patent No. 3326656, mailed on Jul. 14, 2022, 11 pages.
Communication of the Board of Appeal for European Patent No. 2618860, mailed May 4, 2023, 4 pages.
Decision by a different Opposition Division for European Application No. 11802142.7, mailed on Sep. 24, 2021, 22 pages.
Decision by Opposition Division re the Opposition of European Patent No. 2773383, revoking a patent with claims essentially corresponding to the claims presented in the new requests dated Sep. 24, 2021, 22 pages.
Decision revoking the European Patent (Art. 101 (3)(b) EPC) for European Patent No. 2773383, mailed on Sep. 24, 2021, 56 pages.
Dempsey D.J., “Sterilization of Medical Devices: A Review,” Journal of Biomaterials Applications, Jan. 1989, vol. 3, pp. 454-523.
Hoxey E., “Sterilization—Regulatory Requirements and Supporting Standards,” BSI National Standards Body, Medical Device White Paper Series, Publication Date Unknown, 27 pages.
Information about the result of oral proceedings for European Application No. 17203441.5, mailed on Sep. 13, 2022, 2 pages.
Interlocutory Decision in Opposition and Accompanying Items for European Patent No. 3146986, mailed on Feb. 23, 2022, 28 pages.
Letter of the Opponent for the European Patent No. 2773383, mailed on Jun. 15, 2022, 57 pages.
Maintenance of the patent with the documents specified in the final decision, re the opposition of European patent No. EP3146986, mailed on Jun. 7, 2022, 1 page.
Opponent's Written Submission in Preparation for the Oral Proceedings, the Opposition of European Patent No. 3146986, dated Dec. 7, 2021, 1 page.
Proprietor's Written Submission in the Opposition Proceedings for European Patent No. 3326656, dated Jul. 13, 2022, 65 pages.
Statement of Grounds of Appeal filed by proprietor for European patent No. 2773383, mailed on Feb. 2, 2022, 53 pages.
Statement of Grounds of Appeal for European Patent No. 3326656, mailed on Feb. 16, 2023, 125 pages.
Summons to Attend Oral Proceedings pursuant to Rule 115(1) for European Patent No. 3326656, mailed on Dec. 16, 2021, 17 pages.
Summons to Attend Oral Proceedings pursuant to rule 115(1) EPC for Application No. 11802142.7, mailed on Jun. 3, 2020, 20 pages.
Termination of the Opposition Proceedings with Maintenance of European Patent No. 2618860, dated Jul. 3, 2023, 1 page.
Termination of the Opposition Proceedings with Maintenance of European Patent No. 3146986, dated Jul. 8, 2022, 1 page.
Transmittal of decision summons for the Opposition of European Patent No. EP3326656, mailed on Oct. 6, 2022, 27 pages.
Withdrawal of an Appeal—Letter to EPO for European Patent No. 2618860, mailed Jun. 28, 2023, 3 pages.
Related Publications (1)
Number Date Country
20220008640 A1 Jan 2022 US
Divisions (1)
Number Date Country
Parent 12746492 US
Child 14455200 US
Continuations (3)
Number Date Country
Parent 15994818 May 2018 US
Child 17381037 US
Parent 14946468 Nov 2015 US
Child 15994818 US
Parent 14455200 Aug 2014 US
Child 14946468 US